Feb, 07 2019 09:00 JST

Source: Lubrizol

Lubrizol LifeSciences to Showcase New Medical Device Applications Lab at MDM West 2019


CLEVELAND, Ohio, Feb, 07 2019 - (ACN Newswire) - The Lubrizol Corporation announces its LifeSciences business will feature a new medical device applications lab. LifeSciences has invested significantly to expand its global development and manufacturing facilities, and the latest investment is a new state-of-the-art medical device applications lab in Brecksville, Ohio. This lab features applications testing, small-scale compounding as well as injection molding for long-term implantables. The 1,800-square foot facility will also focus on accelerated R&D, from polymers to device scale up and testing in a short period of time.

The medical device applications lab is yet another substantial piece of LifeSciences' full-service capabilities. These capabilities and more will be on display at the MD&M West Exposition (Booth #2401), February 5-7. Lubrizol LifeSciences is a preferred medical device development partner, helping customers from concept to commercialization by offering polymer customization, drug-eluting device development and contract manufacturing services. At MD&M, LifeSciences will also highlight a strong presence in the interventional catheter, long-term implant and drug-eluting device markets. In addition, LifeSciences will unveil new dexamethasone-loaded polymers designed to minimize inflammation and help ensure the success of implantable medical devices.

"The new applications lab is another commitment to healthcare companies looking for a full-service development partner. We continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth," states Uwe Winzen, general manager, Lubrizol LifeSciences. "When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process."

Offering more than 90 years of science and technology experience, Lubrizol is uniquely structured to partner with medical device manufacturers by providing proactive innovation, speed to market, and expertise for the most demanding projects. From materials to development and manufacturing, or anything in between - Lubrizol LifeSciences is equipped to support the needs of customers worldwide.

About Lubrizol LifeSciences

Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.

About The Lubrizol Corporation

The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2017 were $6.3 billion. For more information, visit Lubrizol.com.

Media Contact
Ben Patti
(216) 447-5827
[email protected]
www.lubrizol.com/LifeSciences

###

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via Globenewswire

Source: Lubrizol


Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Related Press Release


Lubrizol Announces Global Collaboration with Corbion
June 18 2019 16:30 JST
 
Particle Sciences Expands Controlled Substance Capabilities with Approval of DEA Schedule I Registration
May 29 2019 10:00 JST
 
Lubrizol to Present at the 29th CIMAC World Congress 2019
May 29 2019 10:00 JST
 
Lubrizol Aims at Circular Economy with TPU Solutions for Footwear
May 17 2019 08:00 JST
 
Lubrizol Announces Collaboration with Ultimaker's Material Alliance Program
May 15 2019 09:00 JST
 
Ground Breaking Ceremony at New Lubrizol LUCANT Plant
April 30 2019 08:00 JST
 
Lubrizol's Diamond Dispersions Business Wins Queen's Award for International Trade
April 23 2019 23:00 JST
 
Lubrizol to Feature New Bio TPU Grades for 3D Printing and Molded Parts at Plastteknik Fair 2019
April 18 2019 07:30 JST
 
Lubrizol is Ready for ILSAC GF-6 - Announcing Lubrizol(R) PV1510 Additive Technology for the GF-6 Specification
April 16 2019 07:00 JST
 
Lubrizol Showcases Renewable-Sourced Estane(R) 3D ECO TPU for 3D Printing at RAPID + TCT 2019
April 12 2019 20:30 JST
 
More Press release >>

Latest Press Release


More Latest Release >>